CLINICAL TRIALS PROFILE FOR CHANTIX
✉ Email this page to a colleague
505(b)(2) Clinical Trials for chantix
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
OTC | NCT03557294 ↗ | Varenicline OTC Trial on Efficacy and Safety | Recruiting | Los Angeles Clinical Trials | Phase 4 | 2018-05-07 | The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication. |
OTC | NCT03557294 ↗ | Varenicline OTC Trial on Efficacy and Safety | Recruiting | National Institute on Drug Abuse (NIDA) | Phase 4 | 2018-05-07 | The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication. |
OTC | NCT03557294 ↗ | Varenicline OTC Trial on Efficacy and Safety | Recruiting | Pfizer | Phase 4 | 2018-05-07 | The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication. |
OTC | NCT03557294 ↗ | Varenicline OTC Trial on Efficacy and Safety | Recruiting | University of Nevada, Reno | Phase 4 | 2018-05-07 | The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication. |
OTC | NCT03557294 ↗ | Varenicline OTC Trial on Efficacy and Safety | Recruiting | Arizona State University | Phase 4 | 2018-05-07 | The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for chantix
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00455650 ↗ | Study of the Effects of Mecamylamine and Varenicline in Schizophrenia | Completed | National Alliance for Research on Schizophrenia and Depression | N/A | 2007-03-01 | We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body. |
NCT00455650 ↗ | Study of the Effects of Mecamylamine and Varenicline in Schizophrenia | Completed | The Bowman Family Foundation | N/A | 2007-03-01 | We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body. |
NCT00455650 ↗ | Study of the Effects of Mecamylamine and Varenicline in Schizophrenia | Completed | Massachusetts General Hospital | N/A | 2007-03-01 | We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body. |
NCT00492349 ↗ | Varenicline Adjunctive Treatment in Schizophrenia | Completed | Stanley Medical Research Institute | Phase 4 | 2007-05-01 | The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking cessation in schizophrenia patients. |
NCT00492349 ↗ | Varenicline Adjunctive Treatment in Schizophrenia | Completed | University of Maryland | Phase 4 | 2007-05-01 | The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking cessation in schizophrenia patients. |
NCT00492349 ↗ | Varenicline Adjunctive Treatment in Schizophrenia | Completed | University of Maryland, Baltimore | Phase 4 | 2007-05-01 | The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking cessation in schizophrenia patients. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for chantix
Condition Name
Clinical Trial Locations for chantix
Trials by Country
Clinical Trial Progress for chantix
Clinical Trial Phase
Clinical Trial Sponsors for chantix
Sponsor Name